首页> 外文期刊>ACS medicinal chemistry letters >Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor
【24h】

Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor

机译:共价kRASG12C抑制剂的化学蛋白质组学特征

获取原文
获取原文并翻译 | 示例
           

摘要

The KRASG12C protein product is an attractive, yet challenging, target for small molecule inhibition. One option for therapeutic intervention is to design small molecule ligands capable of binding to and inactivating KRASG12C via formation of a covalent bond to the sulfhydryl group of cysteine 12. In order to better understand the cellular off-target interactions of Compound 1 , a covalent KRASG12C inhibitor, we have completed a series of complementary chemical proteomics experiments in H358 cells. A new thiol reactive probe (TRP) was designed and used to construct a cellular target occupancy assay for KRASG12C. In addition, the thiol reactive probes allowed us to profile potential off-target interactions of Compound 1 with over 3200 cysteine residues. In order to complement the TRP data we designed Compound 2 , an alkyne containing version of Compound 1 , to serve as bait in competitive chemical proteomics experiments. Herein, we describe and compare data from both the TRP and the click chemistry probe pull down experiments.
机译:KRASG12C蛋白质产品是一种吸引力,但挑战性,用于小分子抑制。治疗干预的一种选择是设计能够通过形成与巯基半胱氨酸组12的共价键结合和失活kRASG12C的小分子配体。为了更好地理解化合物1的细胞脱靶相互作用,共价Krasg12C抑制剂,我们已经在H358细胞中完成了一系列互补化学蛋白质组学实验。设计了一种新的硫醇反应性探针(TRP),并用于构建KRASG12C的细胞靶占型测定。此外,硫醇反应性探针允许我们概述B>化合物1的潜在脱靶相互作用,具有超过3200个半胱氨酸残基。为了补充我们设计的TRP数据化合物2,含有含有竞争性化学蛋白质组学实验的含糖的炔烃。在此,我们描述并比较来自TRP的数据和点击化学探针下拉实验。

著录项

  • 来源
    《ACS medicinal chemistry letters》 |2018年第6期|共6页
  • 作者单位

    Discovery Chemistry Research and Technologies and Oncology Research Lilly Research Laboratories Eli Lilly and Company;

    Discovery Chemistry Research and Technologies and Oncology Research Lilly Research Laboratories Eli Lilly and Company;

    Discovery Chemistry Research and Technologies and Oncology Research Lilly Research Laboratories Eli Lilly and Company;

    Discovery Chemistry Research and Technologies and Oncology Research Lilly Research Laboratories Eli Lilly and Company;

    Discovery Chemistry Research and Technologies and Oncology Research Lilly Research Laboratories Eli Lilly and Company;

    Discovery Chemistry Research and Technologies and Oncology Research Lilly Research Laboratories Eli Lilly and Company;

    Discovery Chemistry Research and Technologies and Oncology Research Lilly Research Laboratories Eli Lilly and Company;

    Discovery Chemistry Research and Technologies and Oncology Research Lilly Research Laboratories Eli Lilly and Company;

    Discovery Chemistry Research and Technologies and Oncology Research Lilly Research Laboratories Eli Lilly and Company;

    Discovery Chemistry Research and Technologies and Oncology Research Lilly Research Laboratories Eli Lilly and Company;

    Discovery Chemistry Research and Technologies and Oncology Research Lilly Research Laboratories Eli Lilly and Company;

    Discovery Chemistry Research and Technologies and Oncology Research Lilly Research Laboratories Eli Lilly and Company;

    Discovery Chemistry Research and Technologies and Oncology Research Lilly Research Laboratories Eli Lilly and Company;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;化学;
  • 关键词

    Chemical proteomics; covalent inhibitor; KRASG12C; mass spectrometry; target identification;

    机译:化学蛋白质组学;共价抑制剂;KRASG12C;质谱;目标识别;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号